story of the week
Enfortumab Vedotin and Pembrolizumab for Untreated Advanced Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
N. Engl. J. Med 2024 Mar 07;390(10)875-888, T Powles, BP Valderrama, S Gupta, J Bedke, E Kikuchi, J Hoffman-Censits, G Iyer, C Vulsteke, SH Park, SJ Shin, D Castellano, G Fornarini, JR Li, M Gümüş, N Mar, Y Loriot, A Fléchon, I Duran, A Drakaki, S Narayanan, X Yu, S Gorla, B Homet Moreno, MS van der HeijdenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.